FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

ALSO NOTED: Lilly wins patent fight; Canada OKs Tarceva; Vioxx trial begins; and much more...

Tools

> A US appeals court has upheld Eli Lilly's patent on Sarafem for premenstrual stress. Teva had challenged the patent saying it is an exact copy of Prozac, which is no longer under patent protection. Report

> Cryocor has priced its IPO at $11 per share. Report

> Canadian regulators have approved OSI's Tarceva for lung cancer. Report

> The first trial of Vioxx is set to begin after a jury was selected in the small Texas town of Angleton. Story

> Merck has acquired most of the global rights for the cancer treatment UFT for the treatment of colorectal cancer from Taiho Pharmaceutical. Release

> Acambis has launched a Phase II trial of a weakened smallpox vaccine for patients unable to take a full dose. Report

> The FDA has approved Ranbaxy's anti-retroviral drug Zidovudine for use outside the US. Story

And Finally... Scientists report that they have discovered a simple therapy to reduce the high risk of death from SARS. Article


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about Eli Lilly   colorectal cancer   Ranbaxy   patent   Tarceva   lung cancer   Acambis